Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
DJI's Osmo Action 6 cameras were mounted on LandSpace's reusable Zhuque-3 rocket, capturing first-person footage during launch and reentry without modifications.
Advicenne withdraws its New Drug Application (NDA) for ADV7103 in the U.S. due to additional Chemistry, Manufacturing and Controls (CMC) requirements identified during FDA review.
BioMarin and Ascendis Pharma A/S settled global patent disputes, with Ascendis agreeing to pay BioMarin 20% royalties on Yuviwel sales in the U.S. and 18% in the EU, Brazil, and South Korea until May 2030.
HUTCHMED's SANOVO Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO® significantly improved progression-free survival (PFS) in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China.
Arrowhead Pharmaceuticals presented Phase 3 SHASTA-3 and SHASTA-4 data showing plozasiran reduced acute pancreatitis events by 78% versus placebo in severe hypertriglyceridemia patients.
Alnylam presented new data at ESC Congress 2026 showing vutrisiran's consistent benefits across ATTR-CM patient populations, including those on tafamidis.
Bristol Myers Squibb presented five-year data from the EXPLORER-LTE study at ESC Congress 2026, reinforcing the long-term efficacy and safety of Camzyos (mavacamten) in symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Rosen Law Firm is investigating Tigo Energy (NASDAQ: TYGO) for potential securities claims after the company revised 2026 income projections downward on August 4, 2026.
